On the stock market since 2020, it operates in the world of money and finance. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $107.2M against $2.3B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, VIH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VIH has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.